Arteriosclerosis Thrombosis and Vascular BiologyBiochemistryPeer-reviewed journal article
Single-Cell Multimodal Profiling Highlights Persistent Aortic Smooth Muscle Cell Changes in Diabetic Mice Despite Glycemic Control
Vinay Singh TanwariD, Vajir MalekiD, Jingyi WangiD, Yingjun LuoiD, Naseeb Kaur MalhiiD, Hongpan ZhangiD, Maryam AbdollahiiD, Linda L. LantingiD, Parijat SenapatiiD, Sadhan DasiD, Marpadga A. ReddyiD, Chongzhi ZangiD, Clint L. MilleriD, Zhen CheniD, Rama D NatarajaniD
Abstract
BackgroundType 2 diabetes (T2D) is associated with accelerated vascular complications like hypertension and atherosclerosis. "Phenotypic switching" of vascular smooth muscle cells (SMC), a major driver of these complications, is enhanced in diabetes. Despite adequate glycemic control, SMC dysfunction can persist due to "metabolic memory" of prior hyperglycemia. However, the mechanisms of hyperglycemic memory associated with persistent SMC dysfunction are unclear. Here, leveraging single-cell (sc) multi-omics, we examined the effect of glucose normalization on transcriptomic and epigenomic changes associated with SMC phenotypic transition in T2D mice. MethodsWe treated T2D db/db mice with the antidiabetic drug dapagliflozin (DAPA) (db/dbDAPA) or vehicle (db/db), and non-diabetic control db/+ mice with vehicle for 6 weeks. Dissected aortas were subjected to scRNA-seq, scATAC-seq, and spatial transcriptomics (Xenium) to determine single-cell changes in gene expression and chromatin accessibility. ResultsDAPA treatment conferred effective glycemic control in db/db mice, with significant reductions in blood glucose/hemoglobin A1c. scRNA and scATAC-seq analysis of aortas identified major cell populations, including SMC, fibroblasts, endothelial and immune cells. SMC were further clustered into 9 subtypes, including contractile and fibromyocyte-like cells. Cell composition analysis revealed decreases in contractile SMC and increases in vascular remodeling associated fibromyocyte-like SMC in db/db versus db/+ mice. Interestingly, DAPA did not reverse diabetes-induced decreases in contractile markers but reversed changes in several fibromyocyte markers in db/db mice. Pseudotime trajectory analysis revealed increased activities of fibromyocyte enriched transcription factors (TFs) during contractile to fibromyocyte transition. Furthermore, increased expression of TFs regulating fibromyocyte phenotype (e.g. Atf4, Bach1, Hand2, Fosl2) in db/db were partially reversed by DAPA, whereas reduced contractile TF (Mef2c) expression was unchanged. Spatial transcriptomics analysis further mapped aortic cell types within intact aortas and confirmed that DAPA reversed alterations in key fibromyocyte but not contractile genes in db/db mouse aortas. ConclusionsPersistent epigenetic changes may contribute to sustained vascular remodeling and dysfunction in T2D. T2D reduced contractile SMC gene expression and related chromatin accessibility and promoted phenotypic transition to fibromyocytes. These changes are only partially reversed by a widely used antidiabetic drug like DAPA, underscoring the need for more effective therapies that target hyperglycemic memory.
- organism: mouse
- assay: scRNA-seq
- assay: scATAC-seq
- assay: spatial transcriptomics
- research focus: cell type annotation
- research focus: clustering
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: deep learning
- approach: statistical model
- Citations
- 5
- FWCI
- 13.25
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Integrative Analysis of Gene Expression, Protein Abundance, and Metabolomic Profiling Elucidates Complex Relationships in Chronic Hyperglycemia-Induced Changes in Human Aortic Smooth Muscle Cells
Smriti Bohara, Atefeh Bagheri, … Chandrasekhar R. Kothapalli·Journal of Biological EngineeringPeer-reviewed·Oct 29, 2024
- JAK and MEK Pathways as Therapeutic Targets for Saphenous Vein Smooth Muscle Cell Dysfunction in Type 2 Diabetes via Regulation of Mitochondrial Activity
Israel Olapeju Bolanle, Florah Tshepo Moshapa, … Timothy M. Palmer·bioRxiv·Oct 17, 2025
- Role of microRNA-145 in DNA damage signalling and senescence in vascular smooth muscle cells of Type 2 diabetic patients
K. E. Hemmings, K. Riches-Suman, … K. E. Porter·bioRxiv·Aug 12, 2020
- Tissue-specific endothelial cell heterogeneity in human type 2 diabetes
Alexander-Francisco Bruns, Oliver Ian Brown, … Mark T. Kearney·bioRxiv·Dec 3, 2025
- The mitochondrial regulation of smooth muscle cell proliferation in type 2 diabetes
Olha M. Koval, Emily K. Nguyen, … Isabella M. Grumbach·bioRxiv·Feb 15, 2023
- Multi-organ single-cell RNA-sequencing reveals early hyperglycaemia responses that converge on fibroblast dysregulation
A. T. Braithwaite, N. Akbar, … R. P. Choudhury·bioRxiv·Aug 7, 2023